Vogelxo

Orchitis, Puberty, Delayed, Gonadotrophin releasing hormone deficiency + 9 more

Treatment

17 FDA approvals

3 Active Studies for Vogelxo

What is Vogelxo

Testosterone

The Generic name of this drug

Treatment Summary

Testosterone is a hormone used to treat conditions where the body does not produce enough of the hormone naturally. It works by blocking the androgen receptor, which helps produce the male sex organs and other male sexual characteristics. Testosterone was first isolated from a sample in 1935 and then synthesized.

Androderm

is the brand name

Vogelxo Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Androderm

Testosterone

1995

90

Approved as Treatment by the FDA

Testosterone, commonly known as Androderm, is approved by the FDA for 17 uses including Spermatic Cord Torsion and Puberty, Delayed .

Spermatic Cord Torsion

Helps manage Torsion of testis

Puberty, Delayed

Used to treat Puberty, Delayed in combination with Testosterone enanthate

Hypogonadism

Helps manage Hypergonadotropic Hypogonadism

Breast

Used to treat inoperable, metastatic Breast cancer in combination with Testosterone enanthate

Torsion of testis

Helps manage Torsion of testis

Hypothalamo-pituitary disorder

Helps manage Hypothalamo-pituitary disorder

Delayed Puberty

Used to treat Puberty, Delayed in combination with Testosterone enanthate

Orchitis

Helps manage Orchitis

Orchitis

Helps manage Orchitis

Hypergonadotropic Hypogonadism

Helps manage Hypergonadotropic Hypogonadism

Hypogonadotropic hypogonadism

Gonadotrophin releasing hormone deficiency

Helps manage Gonadotrophin releasing hormone deficiency

1 to 5 years post-menopausal

Used to treat 1 to 5 years post-menopausal in combination with Testosterone enanthate

Anorchia

Helps manage vanishing testis syndrome

Orchidectomy

Helps manage Orchidectomy

inoperable, metastatic Breast cancer

Used to treat inoperable, metastatic Breast cancer in combination with Testosterone enanthate

Hypogonadism

Helps manage Idiopathic Hypogonadotropic Hypogonadism

Effectiveness

How Vogelxo Affects Patients

Testosterone helps to form the sex organs and characteristics that are typically seen in men. How long it stays in the body can vary from person to person, with a typical half-life of 10-100 minutes. The amount of testosterone in an adult man's body usually ranges from 300-1000ng/dL, making it a relatively safe drug. It is important to caution patients about the potential for children to be exposed to testosterone when using topical products.

How Vogelxo works in the body

The androgen receptor is a protein that is found in the cytoplasm and binds to molecules like testosterone and dihydrotestosterone. Once bound, the androgen receptor changes shape and is transported to the nucleus. This allows it to bind to DNA and cause certain genes to be expressed. Testosterone and dihydrotestosterone are responsible for the formation of male sex organs, as well as secondary physical characteristics like facial and body hair, a deeper voice, and changes in muscle and fat distribution.

When to interrupt dosage

The quantity of Vogelxo is reliant upon the diagnosed disorder, like Gonadotrophin releasing hormone deficiency, Orchidectomy and Orchitis. The degree of dosage is contingent on the technique of delivery specified in the table beneath.

Condition

Dosage

Administration

Breast

, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg

, Transdermal, Gel - Transdermal, Gel, Injection, solution - Intramuscular, Intramuscular, Gel - Topical, Topical, Subcutaneous, Pellet - Subcutaneous, Pellet, Solution, Solution - Topical, Tablet, Buccal, Pellet - Oral, Oral, Capsule, Capsule - Oral, Gel - Nasal, Patch - Transdermal, Nasal, Gel, metered - Topical, Gel, metered, Patch, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable, Pellet, implantable - Parenteral, Parenteral, Injection - Intramuscular, Tablet - Buccal, Suspension, Suspension - Intramuscular

Orchitis

, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg

, Transdermal, Gel - Transdermal, Gel, Injection, solution - Intramuscular, Intramuscular, Gel - Topical, Topical, Subcutaneous, Pellet - Subcutaneous, Pellet, Solution, Solution - Topical, Tablet, Buccal, Pellet - Oral, Oral, Capsule, Capsule - Oral, Gel - Nasal, Patch - Transdermal, Nasal, Gel, metered - Topical, Gel, metered, Patch, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable, Pellet, implantable - Parenteral, Parenteral, Injection - Intramuscular, Tablet - Buccal, Suspension, Suspension - Intramuscular

Puberty, Delayed

, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg

, Transdermal, Gel - Transdermal, Gel, Injection, solution - Intramuscular, Intramuscular, Gel - Topical, Topical, Subcutaneous, Pellet - Subcutaneous, Pellet, Solution, Solution - Topical, Tablet, Buccal, Pellet - Oral, Oral, Capsule, Capsule - Oral, Gel - Nasal, Patch - Transdermal, Nasal, Gel, metered - Topical, Gel, metered, Patch, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable, Pellet, implantable - Parenteral, Parenteral, Injection - Intramuscular, Tablet - Buccal, Suspension, Suspension - Intramuscular

Gonadotrophin releasing hormone deficiency

, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg

, Transdermal, Gel - Transdermal, Gel, Injection, solution - Intramuscular, Intramuscular, Gel - Topical, Topical, Subcutaneous, Pellet - Subcutaneous, Pellet, Solution, Solution - Topical, Tablet, Buccal, Pellet - Oral, Oral, Capsule, Capsule - Oral, Gel - Nasal, Patch - Transdermal, Nasal, Gel, metered - Topical, Gel, metered, Patch, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable, Pellet, implantable - Parenteral, Parenteral, Injection - Intramuscular, Tablet - Buccal, Suspension, Suspension - Intramuscular

1 to 5 years post-menopausal

, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg

, Transdermal, Gel - Transdermal, Gel, Injection, solution - Intramuscular, Intramuscular, Gel - Topical, Topical, Subcutaneous, Pellet - Subcutaneous, Pellet, Solution, Solution - Topical, Tablet, Buccal, Pellet - Oral, Oral, Capsule, Capsule - Oral, Gel - Nasal, Patch - Transdermal, Nasal, Gel, metered - Topical, Gel, metered, Patch, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable, Pellet, implantable - Parenteral, Parenteral, Injection - Intramuscular, Tablet - Buccal, Suspension, Suspension - Intramuscular

Hypothalamo-pituitary disorder

, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg

, Transdermal, Gel - Transdermal, Gel, Injection, solution - Intramuscular, Intramuscular, Gel - Topical, Topical, Subcutaneous, Pellet - Subcutaneous, Pellet, Solution, Solution - Topical, Tablet, Buccal, Pellet - Oral, Oral, Capsule, Capsule - Oral, Gel - Nasal, Patch - Transdermal, Nasal, Gel, metered - Topical, Gel, metered, Patch, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable, Pellet, implantable - Parenteral, Parenteral, Injection - Intramuscular, Tablet - Buccal, Suspension, Suspension - Intramuscular

Orchidectomy

, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg

, Transdermal, Gel - Transdermal, Gel, Injection, solution - Intramuscular, Intramuscular, Gel - Topical, Topical, Subcutaneous, Pellet - Subcutaneous, Pellet, Solution, Solution - Topical, Tablet, Buccal, Pellet - Oral, Oral, Capsule, Capsule - Oral, Gel - Nasal, Patch - Transdermal, Nasal, Gel, metered - Topical, Gel, metered, Patch, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable, Pellet, implantable - Parenteral, Parenteral, Injection - Intramuscular, Tablet - Buccal, Suspension, Suspension - Intramuscular

Spermatic Cord Torsion

, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg

, Transdermal, Gel - Transdermal, Gel, Injection, solution - Intramuscular, Intramuscular, Gel - Topical, Topical, Subcutaneous, Pellet - Subcutaneous, Pellet, Solution, Solution - Topical, Tablet, Buccal, Pellet - Oral, Oral, Capsule, Capsule - Oral, Gel - Nasal, Patch - Transdermal, Nasal, Gel, metered - Topical, Gel, metered, Patch, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable, Pellet, implantable - Parenteral, Parenteral, Injection - Intramuscular, Tablet - Buccal, Suspension, Suspension - Intramuscular

Hypogonadism

, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg

, Transdermal, Gel - Transdermal, Gel, Injection, solution - Intramuscular, Intramuscular, Gel - Topical, Topical, Subcutaneous, Pellet - Subcutaneous, Pellet, Solution, Solution - Topical, Tablet, Buccal, Pellet - Oral, Oral, Capsule, Capsule - Oral, Gel - Nasal, Patch - Transdermal, Nasal, Gel, metered - Topical, Gel, metered, Patch, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable, Pellet, implantable - Parenteral, Parenteral, Injection - Intramuscular, Tablet - Buccal, Suspension, Suspension - Intramuscular

Hypogonadotropic hypogonadism

, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg

, Transdermal, Gel - Transdermal, Gel, Injection, solution - Intramuscular, Intramuscular, Gel - Topical, Topical, Subcutaneous, Pellet - Subcutaneous, Pellet, Solution, Solution - Topical, Tablet, Buccal, Pellet - Oral, Oral, Capsule, Capsule - Oral, Gel - Nasal, Patch - Transdermal, Nasal, Gel, metered - Topical, Gel, metered, Patch, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable, Pellet, implantable - Parenteral, Parenteral, Injection - Intramuscular, Tablet - Buccal, Suspension, Suspension - Intramuscular

Anorchia

, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg

, Transdermal, Gel - Transdermal, Gel, Injection, solution - Intramuscular, Intramuscular, Gel - Topical, Topical, Subcutaneous, Pellet - Subcutaneous, Pellet, Solution, Solution - Topical, Tablet, Buccal, Pellet - Oral, Oral, Capsule, Capsule - Oral, Gel - Nasal, Patch - Transdermal, Nasal, Gel, metered - Topical, Gel, metered, Patch, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable, Pellet, implantable - Parenteral, Parenteral, Injection - Intramuscular, Tablet - Buccal, Suspension, Suspension - Intramuscular

Hypogonadism

, 0.01 mg/mg, 0.05 mg/mg, 75.0 mg, 100.0 mg/mL, 0.0162 mg/mg, 0.2 mg/hour, 0.4 mg/hour, 200.0 mg/mL, 30.0 mg/mL, 30.0 mg, 100.0 mg, 200.0 mg, 37.5 mg, 25.0 mg, 50.0 mg, 87.5 mg, 40.0 mg, 1.0 %, 4.5 %, 0.03 mg/hour, 5.5 mg, 0.1 mg/mg, 250.0 mg/mL, 0.0125 mg/mg, 12.5 mg, 12.2 mg, 24.3 mg, 0.025 mg/mg, 0.25 mg/hour, 0.5 mg/hour, 0.055 mg/mg, 0.00162 mg/mg, 0.02025 mg/mg, 0.0405 mg/mg, 30.0 mg/pump actuation, 12.5 mg/pump actuation, 60.0 mg

, Transdermal, Gel - Transdermal, Gel, Injection, solution - Intramuscular, Intramuscular, Gel - Topical, Topical, Subcutaneous, Pellet - Subcutaneous, Pellet, Solution, Solution - Topical, Tablet, Buccal, Pellet - Oral, Oral, Capsule, Capsule - Oral, Gel - Nasal, Patch - Transdermal, Nasal, Gel, metered - Topical, Gel, metered, Patch, Solution - Transdermal, Gel, metered - Nasal, Gel, metered - Transdermal, Pellet, implantable - Subcutaneous, Pellet, implantable, Pellet, implantable - Parenteral, Parenteral, Injection - Intramuscular, Tablet - Buccal, Suspension, Suspension - Intramuscular

Warnings

Vogelxo has two contraindications and should not be taken for the conditions illustrated in the following table.

Vogelxo Contraindications

Condition

Risk Level

Notes

suspected pregnancy

Do Not Combine

Breast Cancer

Do Not Combine

There are 20 known major drug interactions with Vogelxo.

Common Vogelxo Drug Interactions

Drug Name

Risk Level

Description

Abemaciclib

Major

The metabolism of Abemaciclib can be increased when combined with Testosterone.

Acalabrutinib

Major

The metabolism of Acalabrutinib can be increased when combined with Testosterone.

Alectinib

Major

The metabolism of Alectinib can be increased when combined with Testosterone.

Aminophylline

Major

The metabolism of Aminophylline can be increased when combined with Testosterone.

Astemizole

Major

The metabolism of Astemizole can be increased when combined with Testosterone.

Vogelxo Toxicity & Overdose Risk

There is limited information available on the effects of a testosterone product overdose. If an injectable product is overdosed on, the patient may suffer a stroke. Treatment for testosterone overdoses should involve ceasing the product, washing off any topical products, and providing supportive care.

Vogelxo Novel Uses: Which Conditions Have a Clinical Trial Featuring Vogelxo?

Ten active studies are examining the efficacy of Vogelxo in providing relief from Orchitis, Testicular Torsion and Hypothalamo-pituitary Dysfunctions.

Condition

Clinical Trials

Trial Phases

Hypothalamo-pituitary disorder

0 Actively Recruiting

1 to 5 years post-menopausal

0 Actively Recruiting

Hypogonadism

0 Actively Recruiting

Orchitis

0 Actively Recruiting

Spermatic Cord Torsion

0 Actively Recruiting

Orchidectomy

0 Actively Recruiting

Breast

0 Actively Recruiting

Hypogonadotropic hypogonadism

0 Actively Recruiting

Puberty, Delayed

0 Actively Recruiting

Gonadotrophin releasing hormone deficiency

0 Actively Recruiting

Anorchia

0 Actively Recruiting

Hypogonadism

3 Actively Recruiting

Phase 2

Vogelxo Reviews: What are patients saying about Vogelxo?

2.7

Patient Review

9/18/2017

Vogelxo for Deficiency of a Substance that Promotes Masculinization

I had a lot of deep pimples while using this medication. They were below the surface of my skin and really hurt. The cream was also tacky and made my skin feel uncomfortable. I only gave it one star because I shouldn't have had a painful rash.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about vogelxo

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is Vogelxo generic?

"No generic form of this product exists. Counterfeit versions of the drug sold by fraudulent online pharmacies may be unsafe."

Answered by AI

How many doses in testosterone pump?

"The recommended dose for Vogelxo is 50 mg applied to clean, dry skin once a day. Your doctor may adjust your dose as needed, but the maximum recommended dose is 100 mg once a day."

Answered by AI

How many grams of testosterone per pump?

"A metered-dose pump that delivers 20.25 mg of testosterone in 1.25 g of gel with each pump actuation."

Answered by AI

Is Vogelxo a controlled substance?

"Under the Act, it is unlawful to knowingly or intentionally manufacture, distribute, or dispense, or possess with intent to manufacture, distribute, or dispense, a controlled substance.

Vogelxo contains testosterone, a substance that is regulated under the Controlled Substances Act. It is against the law to knowingly produce, distribute, or dispense this substance, or to possess it with the intent to do so."

Answered by AI

Clinical Trials for Vogelxo

Image of ReproNovo Investigational Site in Garden City, United States.

Leflutrozole for Hypogonadotropic Hypogonadism

18 - 49
Male
Garden City, NY

The goal of this clinical trial is to evaluate three doses of the drug leflutrozole on improvement of semen quality in men with hypogonadotropic hypogonadism, a condition that affects hormone levels and fertility. It will also study the safety of leflutrozole. The main questions it aims to answer are: * Does leflutrozole improve semen quality? * What medical problems do participants experience when taking leflutrozole? Researchers will compare leflutrozole to a placebo (a look-alike substance that contains no drug). Participants will: * Take leflutrozole or a placebo orally once a week for 16 weeks. * Visit the clinic every 4 weeks for checkups and tests. * Provide semen samples to measure changes in semen quality. * Have their blood tested to measure hormone levels and ensure safety. * Be monitored for any side effects.

Phase 2
Recruiting

ReproNovo Investigational Site (+2 Sites)

Medical Director

ReproNovo Aps